Medison Pharma to Commercialize Moderna Covid-19 Vaccine

Medison Pharma, a leading commercial partner for highly innovative therapies in international markets, and Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced a new agreement to commercialize the Moderna Covid Vaccine across Central Eastern Europe and Israel.

Poland, the Czech Republic, Romania, Hungary, Bulgaria, Slovenia, Slovakia, Croatia, Estonia, Ukraine, Moldova, Albania, Bosnia, and Herzegovina, Kosovo, North Macedonia, Latvia, Lithuania, Serbia, Montenegro, and Israel are all covered by the pact.

CEO and Founder of Medison Pharma, Meir Jakobsohn, said, “We are excited to partner with Moderna in 20 markets, covering over 175 million lives across the entire Central Eastern Europe region and in Israel. Moderna’s breakthrough vaccine and Medison’s international commercialization platform for highly innovative treatments, makes our partnership a natural fit.”Medison is a multinational pharmaceutical firm that focuses on bringing cutting-edge therapies to patients in worldwide markets. Medison offers a full range of integrated services for enterprises looking to build a presence in international markets, drawing on a 25-year track record and partnerships with major biotech companies.

Medison also has a corporate venture arm with a dedicated research and assessment team with extensive scientific and business knowledge. Moderna’s mRNA platform has enabled the creation of treatments and vaccines for infectious illnesses, immuno-oncology, rare illnesses, cardiovascular disorders, and auto-immune disorders, thanks to continual improvements in basic and applied mRNA research, delivery technology, and manufacturing.There are currently 24 development programs in these therapeutic areas, with 13 of them having entered the clinic. For the previous six years, Science has rated Moderna as a top biopharmaceutical employer.